Literature DB >> 15951740

Patient satisfaction with antihypertensive therapy.

K Chen1, C-F Chiou, C A Plauschinat, F Frech, A Harper, R Dubois.   

Abstract

The objective of the study was to assess factors associated with treatment satisfaction among patients receiving antihypertensive therapy. A weighted cross-sectional online survey was conducted with hypertensive patients participating in a chronic disease panel in the US. Patients on monotherapy with medications from the following classes were identified: ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta blockers (BBs), calcium channel blockers (CCBs), and diuretics. The control group included patients without treatment. Pairwise comparisons between groups were conducted for factors that may affect patients' satisfaction. The study population had a mean age of 54.7+/-14.2 years and was 56.7% female. Participants with blood pressure (BP) controlled to JNC 7 guidelines were more satisfied with their medication than those with uncontrolled BP (90.3 vs 71.5%, P<0.05). Patients who had not experienced adverse events had higher satisfaction than patients experiencing adverse events (90.9 vs 75.8%, P<0.05). The most frequently self-reported adverse events were frequent urination, sexual dysfunction, and fatigue ranging from 7.0 to 9.6% across classes. The adverse event rates differed by class and were lowest among the ARBs. Patients on ARBs were the most likely to have switched from a previous antihypertensive class as compared to other classes (57.1% ARBs vs 49.8% ACEIs, 38.7% diuretics, 36.3% CCBs, and 31.7% BBs). Physician recommendation was the most common reason for switching. In conclusion, the ability to effectively treat hypertension depends upon a patient's satisfaction with antihypertensive therapy, which may be improved by achieving BP control and minimizing the occurrence of adverse events.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951740     DOI: 10.1038/sj.jhh.1001899

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

1.  Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes.

Authors:  Mary E Tinetti; Gail J McAvay; Terri R Fried; Heather G Allore; Joanna C Salmon; Joanne M Foody; Luann Bianco; Sandra Ginter; Liana Fraenkel
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

2.  Rhinorrhea, cough and fatigue in patients taking sitagliptin.

Authors:  James N Baraniuk; Mary J Jamieson
Journal:  Allergy Asthma Clin Immunol       Date:  2010-05-12       Impact factor: 3.406

3.  Association between antihypertensive medication use and non-cardiovascular outcomes in older men.

Authors:  Joseph V Agostini; Mary E Tinetti; Ling Han; Peter Peduzzi; Joanne M Foody; John Concato
Journal:  J Gen Intern Med       Date:  2007-09-25       Impact factor: 5.128

4.  Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study.

Authors:  Giuseppe Rossetti; Samuele Pizzocri; Francesco Brasca; Marta Pozzi; Laura M Beltrami; Giovanni B Bolla; Roberta Famiani; Barbara Caimi; Stefano Omboni; Fabio Magrini; Stefano Carugo
Journal:  Curr Ther Res Clin Exp       Date:  2008-06

5.  How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey.

Authors:  Deborah A Marshall; F Reed Johnson; Nathalie A Kulin; Semra Ozdemir; Judith M E Walsh; John K Marshall; Stephanie Van Bebber; Kathryn A Phillips
Journal:  Health Econ       Date:  2009-12       Impact factor: 3.046

6.  Antihypertensive drug treatment changes in the general population: the CoLaus study.

Authors:  Vanessa Christe; Gérard Waeber; Peter Vollenweider; Pedro Marques-Vidal
Journal:  BMC Pharmacol Toxicol       Date:  2014-03-31       Impact factor: 2.483

7.  New-user persistence with antihypertensives and prescription drug cost-sharing.

Authors:  Becky A Briesacher; M Rhona Limcangco; Feride Frech-Tamas
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-11       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.